Raytheon Technologies Corp vs Teladoc Health Inc — how do they compare? Raytheon Technologies Corp trades at $184.77 (market cap $242.95B), while Teladoc Health Inc trades at $5.54 (market cap $1.01B). The key difference: Raytheon Technologies Corp is far larger — about 240.5× Teladoc Health Inc's market cap, and Raytheon Technologies Corp pays a 1.62% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raytheon Technologies Corp for 78 Days and Teladoc Health Inc for 39 Days on average.
| RTX | TDOC | |
|---|---|---|
Market Cap | $242.95B | $1.01B |
Volume | 4,213,378 | 3,622,440 |
Sector | Industrials | Health |
52-Week High | $225.49 | $9.72 |
52-Week Low | $157.00 | $4.47 |
Typical Hold Time | 78 Days | 39 Days |
Enterprise Value | $273.50B | $1.27B |
Dividend Yield | 1.62% | — |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $184.32, up 0.56% today, with strong fundamental momentum as revenue grew to $88.6B in 2025 and net income reached $6.73B. The company has beaten earnings estimates for three consecutive quarters, supported by a massive $289B backlog. Technical indicators show a bearish short-term trend despite bullish oscillators, while analyst consensus remains strongly positive with a $237.60 price target.
RTX presents a compelling investment case with robust defense sector tailwinds and consistent earnings outperformance. Key risks include execution challenges in managing the large backlog and potential defense budget volatility. The stock offers 29% upside to consensus targets, making it attractive for long-term investors despite near-term technical weakness.
Teladoc Health (TDOC) trades at $5.54, down 3.99% in the latest session, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with oversold conditions while fundamentals reveal a mixed picture - strong gross margins of 68.97% but persistent net losses. Recent management changes and legal investigations add uncertainty, though the company maintains solid cash flow from operations of $294.36 million.
TDOC presents a high-risk opportunity with significant upside potential given the $8.83 consensus price target, representing 59% upside. However, continued net losses, negative cash flow trends, and competitive pressures in telehealth create substantial execution risk. The stock's current valuation at 0.4x sales appears attractive if the company can achieve profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →